Bioventus BVS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $34.54M+26.6% | $27.27M+192% | $9.35M+1,967% | -$501K+98.9% | -$43.99M+6.5% | ||
| $46.35M-1.4% | $47.01M-1.5% | $47.72M-1.8% | $48.59M-2.1% | $49.64M+0.2% | ||
| $13.52M+6.7% | $12.67M+12.7% | $11.25M+6.5% | $10.56M-16.8% | $12.7M-4.3% | ||
| -$817K+10.1% | -$909K— | —— | —— | —— | ||
| $0+100% | -$81K+78.3% | -$373K+0.3% | -$374K-0.3% | -$373K-27.7% | ||
| $836K-33.4% | $1.26M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$7.8M+9.0% | -$8.57M-186% | $9.96M-22.0% | $12.77M-10.4% | $14.25M-13.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.06M-9.1% | $1.16M-48.6% | $2.26M-13.6% | $2.61M+0.1% | $2.61M-7.1% | ||
| $102.94M+37.9% | $74.67M+33.3% | $56.03M+54.6% | $36.25M+42.3% | $25.47M-34.3% | ||
| $2.31M-9.8% | $2.56M+0.2% | $2.56M+19.0% | $2.15M+39.3% | $1.54M+53.2% | ||
| -$3M+7.8% | -$3.25M-115% | $21.44M-1.9% | $21.85M-5.6% | $23.14M+0.8% | ||
| $40M-11.1% | $45M+28.6% | $35M+40.0% | $25M+25.0% | $20M+33.3% | ||
| $2.04M-1.4% | $2.07M-22.2% | $2.67M-14.6% | $3.12M+29.3% | $2.42M-1.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $19.77M+120% | $9M— | ||
| —— | $697K-14.8% | $817.75K-12.9% | $938.5K-11.4% | $1.06M-10.2% | ||
| -$86.23M-38.8% | -$62.14M+18.8% | -$76.55M-35.3% | -$56.57M-13.7% | -$49.75M+9.4% | ||
| —— | —— | —— | —— | —— | ||
| $13.04M+35.1% | $9.66M— | —— | —— | —— | ||
| $96K-75.5% | $392K-20.2% | $491K-57.7% | $1.16M+32.1% | $878K+239% | ||
| $0+100% | -$81K+78.3% | -$373K+0.3% | -$374K-0.3% | -$373K-27.7% | ||
| $836K-33.4% | $1.26M— | —— | —— | —— | ||
| —— | -$686K-112% | $5.66M-52.9% | $12M-34.6% | $18.34M-25.7% | ||
| —— | $65.77M+33.3% | $49.32M+50.0% | $32.88M+100% | $16.44M— | ||
| —— | $0-100% | $1.13M-50.0% | $2.25M-33.3% | $3.38M-25.0% | ||
| -$844K-2.1% | -$827K-1.7% | -$813K-2.0% | -$797K-2.4% | -$778K-2.6% | ||
| $40M-11.1% | $45M+28.6% | $35M+40.0% | $25M+25.0% | $20M+33.3% | ||
| $634K+164% | $240K— | —— | —— | —— | ||
| —— | —— | —— | $19.77M+120% | $9M— | ||
| —— | —— | —— | —— | $15M— | ||
| $100.63M+39.5% | $72.11M+34.9% | $53.47M+56.8% | $34.1M+42.5% | $23.93M-36.7% | ||
| $100.63M+39.5% | $72.11M+34.9% | $53.47M+56.8% | $34.1M+42.5% | $23.93M-36.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bioventus generate?
- Bioventus (BVS) generated $102.9M in operating cash flow over the trailing twelve months.
- What is Bioventus's free cash flow?
- After $2.3M of capital expenditures, Bioventus's free cash flow was $100.6M over the trailing twelve months, up 320.5% year over year.
- Where does Bioventus's cash flow data come from?
- Every line is extracted from Bioventus's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
